Tag: GlobeNewswire

Pilot program will evaluate autonomous robotic support for linen transport and event operations

AUSTIN, Texas, Nov. 02, 2026 (GLOBE NEWSWIRE) — via IBN – TechForce Robotics, Inc. (“TechForce”), a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), today announced a 60-day pilot program at Fairmont Austin focused on autonomous robotic support across select hotel operations.

During the pilot, TechForce robotic systems will autonomously transport soiled linens and pool towels across select areas of the property. The robots will be configured around the hotel’s existing workflows, with the goal of reducing manual transport and heavy lifting for team members.

“This pilot is about showing how autonomous robotics can provide practical support in demanding hospitality environments,” said Ried Floco, president and director of TechForce Robotics. “By taking on repetitive material transport, these systems can allow team members to focus their time and attention on other responsibilities.”

About TechForce Robotics, Inc.

TechForce Robotics, Inc., a subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF), is a technology company focused on the development and commercialization of robotics and automation solutions. The company develops autonomous robotic systems and integrated software designed to support workforces, improve operational efficiency and automate repetitive tasks across commercial and enterprise environments. TechForce offers flexible deployment options, including a fully managed subscription model (RaaSP) that includes deployment, maintenance and ongoing support.

About Nightfood Holdings, Inc. (OTCQB: NGTF)

Nightfood Holdings Inc., doing business as TechForce Robotics, is an advanced robotics and automation company focused on delivering intelligent, scalable solutions for industrial and commercial applications. The Company integrates robotics, artificial intelligence, software-driven systems and strategic manufacturing capabilities to address evolving operational needs across multiple industries.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable securities laws. Such statements include expectations regarding manufacturing partnerships, production timelines, future revenue, robotics commercialization, customer deployments, corporate initiatives, potential exchange listing and future growth opportunities. These statements involve risks and uncertainties, and actual results may differ materially from those anticipated. Proposed transactions and commercial initiatives remain subject to applicable agreements, approvals, operational requirements and other conditions. The Company undertakes no obligation to update forward-looking statements except as required by law. Investors should review the Company’s filings with the Securities and Exchange Commission for further information regarding risks and uncertainties.

For more information on Nightfood Holdings, Inc. (OTCQB: NGTF), please visit www.nightfoodholdings.com.

Investor Relations, Media Relations and Corporate Communications

Investor Relations
Nightfood Holdings, Inc
www.nightfoodholdings.com

Media Relations
media@nightfoodholdings.com

Corporate Communications
IBN.Ai
Austin, Texas
www.IBN.Ai
512.354.7000 Office
Editor@IBN.Ai

Adam Steinberg, Mickey Brunton, and Gavin Kolt Strengthen Capital Structure Advisory, GP-Led Secondaries, and Private Capital Markets Capabilities

ST. LOUIS, Nov. 02, 2026 (GLOBE NEWSWIRE) — Stifel Financial Corp. (NYSE: SF) (“Stifel”) today announced the recent additions of Adam Steinberg, Mickey Brunton, and Gavin Kolt to senior leadership roles across its Capital Solutions platform. All three are serving as Managing Directors based in New York, and represent important additions to Stifel’s capabilities in capital structure advisory, GP-led secondaries, and private capital markets.

The appointments deepen Stifel’s ability to advise corporate and financial sponsor clients across the full capital structure. Stifel’s Capital Solutions platform integrates its Equity Capital Markets, Leveraged Finance, Private Capital Advisory, and Capital Structure Advisory groups with the firm’s M&A and industry coverage bankers to provide clients with a comprehensive range of financing and strategic advisory solutions.

“Stifel’s Capital Solutions Group has been purpose-built to provide our corporate and sponsor clients the full spectrum of advisory and financing options on a single platform,” said Seth Rubin, Head of Global Equity Capital Markets at Stifel. “Bringing in Adam, Mickey, and Gavin as trusted experts in their markets significantly enhances our ability to drive best outcomes for our clients.”

Adam Steinberg joins as Head of Stifel’s Capital Structure Advisory Group, which advises public and private companies, and their stakeholders, across a full range of balance sheet solutions. Mr. Steinberg brings 25 years of investment banking and asset management experience, advising clients on mergers and acquisitions, financing transactions, restructurings, and other complex capital structure matters across a wide range of industries. Before joining Stifel, Mr. Steinberg was a Managing Director at Moelis & Company. Previously, he was a credit analyst at Lonestar Capital Management, and earlier in his career was a Vice President in the Recapitalization & Restructuring Group at Jefferies.

Mickey Brunton serves as Co-Head of Eaton Partners’ GP-led Secondaries Advisory Group, advising financial sponsors on GP-led secondary transactions and innovative liquidity solutions. Through Eaton Partners, clients benefit from access to Stifel’s broader investment banking platform, including primary fundraising, GP and LP led secondary advisory, direct/co-investment fundraising, and GP strategic capital advisory. Throughout his career, Mr. Brunton has advised on and structured approximately $5 billion in secondary transactions. Prior to joining Eaton Partners, Mr. Brunton was Head of Secondaries at Connaught LLC, and before that, served in Jefferies’ Private Capital Advisory group.

Gavin Kolt is Head of Stifel’s Private Capital Markets Group, advising companies and their sponsors on privately negotiated equity, structured equity, and equity-linked financings for growth, acquisitions, liquidity, and balance sheet optimization. Mr. Kolt brings more than 25 years of private capital markets experience and has advised on and structured transactions totaling more than $60 billion. Most recently, Mr. Kolt was a Managing Director and Head of Equity Private Capital Markets at Baird. Previously, he was a Managing Director at Moelis & Company, a Director at Merrill Lynch, and began his investment banking career at Sheshunoff & Co.

These hires build on Stifel’s continued growth in its investment banking platform, which includes more than 750 professionals worldwide.

Stifel Company Information
Stifel Financial Corp. (NYSE: SF) is a diversified financial services firm providing wealth management, commercial and investment banking, trading, and research services to individuals, institutions, and municipalities. Founded in 1890 and headquartered in St. Louis, Missouri, the firm operates more than 400 offices across the United States and in major global financial centers. As a firm where success meets success, Stifel works closely with retail and institutional clients aiming to transform opportunities into achievement. To learn more about Stifel, please visit the Company’s website at www.stifel.com. For global disclosures, please visit www.stifel.com/investor-relations/press-releases.

About Eaton Partners
Eaton Partners, a Stifel Company, is one of the world’s largest private capital advisory firms, having raised more than $140 billion across more than 190 highly differentiated alternative investment funds and offerings. Founded in 1983, Eaton advises and raises institutional capital for investment managers across alternative strategies – private equity, private credit, real assets, and real estate in both the primary and secondary markets. Eaton Partners maintains offices and operates throughout North America, Europe, and Asia. Eaton Partners is a division of Stifel, Nicolaus & Company, Incorporated, Member SIPC and NYSE. For more information, please visit https://eaton-partners.com/.

Media Contacts
Neil Shapiro, +1 (212) 271-3447, shapiron@stifel.com
Evan Roesen, +1 (212) 271-3760, roesene@stifel.com

Investor Relations Contact
Joel Jeffrey, +1 (212) 271-3610, investorrelations@stifel.com

SEATTLE and VANCOUVER, British Columbia, Nov. 02, 2026 (GLOBE NEWSWIRE) — Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced that the Compensation Committee of Achieve’s Board of Directors approved stock option grants to purchase an aggregate of 97,000 shares of its common stock and restricted stock unit (“RSU”) awards covering an aggregate of 97,000 shares of its common stock for three new employees.

The stock options have an exercise price equal to the closing price of Achieve’s common stock on the applicable grant date. Each stock option has a four-year vesting period and will vest as to 25% of the shares underlying the stock option on the first anniversary following commencement of employment. The remaining 75% of the shares underlying the stock option will vest in 36 equal monthly installments thereafter, subject to the employee’s continued service through each applicable vesting date.

Each RSU award represents the right to receive one share of Achieve’s common stock upon vesting, subject to the recipient’s continued service. The RSUs will vest over four years with 25% of the underlying shares vesting on each anniversary following commencement of employment, subject to the employee’s continued service through each applicable vesting date.

The stock options and RSU awards are subject to the terms and conditions of the 2024 Equity Inducement Plan, as well as the terms and conditions of the stock option agreement or RSU award agreement covering the grants and were made as an inducement material to the individuals entering into employment with Achieve in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytisinicline
There are approximately 25 million adults in the United States who smoke combustible cigarettes.¹ Cytisinicline is an investigational compound that binds to nicotinic receptors. It is being developed as an aid to smoking cessation treatment in adults and as an aid to nicotine e-cigarette cessation.

About Achieve Life Sciences, Inc.
Achieve Life Sciences, Inc. is a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence. Achieve’s New Drug Application (NDA) for cytisinicline for smoking cessation in adults is supported by two successfully completed Phase 3 studies and an open-label long-term safety study. Achieve has also completed a Phase 2 study of cytisinicline in nicotine e-cigarette cessation, conducted an end-of-Phase 2 meeting with the FDA, and has received Breakthrough Therapy designation for the vaping cessation indication.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements Achieve makes regarding the timing, nature and outcome of cytisinicline clinical development and regulatory review and approval, data results, the timing, nature and success of Achieve’s commercialization activities, the potential market size for cytisinicline, the potential benefits, efficacy, safety and tolerability of cytisinicline, the development and effectiveness of new treatments, the performance of Achieve’s third-party manufacturing partners, the successful launch and commercialization of cytisinicline, and statements concerning Achieve Life Sciences’ future plans and prospects. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Achieve may not actually achieve its plans or product development goals in a timely manner, if at all, or otherwise carry out its intentions or meet its expectations or projections disclosed in these forward-looking statements. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including those described in Achieve’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q. Achieve undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

Achieve Contact
Nicole Jones
VP, Strategic Communications and Stakeholder Relations
ir@achievelifesciences.com
media@achievelifesciences.com
425-686-1510

Reference
¹Agaku I. Tobacco Product Use among U.S. Adults, 2023–2024, NEJM Evidence, doi: 10.1056/EVIDpha2500339.

ARLINGTON, Va., Nov. 02, 2026 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) announced the acquisition of American Choice Healthcare MSSP, LLC (ACH), a wholly-owned subsidiary of Cano Health. The Accountable Care Organization (ACO) will care for more than 36,000 attributed lives in the Medicare Shared Savings Program (MSSP) starting January 1, 2027.

Privia Health paid approximately $36 million at closing using cash on its balance sheet. The transaction is expected to have minimal impact on all key metrics in 2026 and will positively contribute to Attributed Lives and Adjusted EBITDA in 2027.

This strategic transaction further scales Privia Care Partners, adding attributed lives in both existing and new states, and also offers a compelling synergy opportunity for providers to join Privia’s Medical Groups for a full suite of services and technology platform.

“Adding ACH to our national network of ACOs underscores Privia Health’s ability to replicate our differentiated and flexible operating model with new practice partners across the country,” said Sam Starbuck, Senior Vice President and President, Privia Care Partners. “We look forward to collaborating with these physicians and their practices, leveraging our population health and value-based care expertise to enhance the patient experience, improve outcomes, and lower costs.”

About Privia Health

Privia Health™ is one of the largest physician enablement companies in the United States with a presence in 25 states and the District of Columbia. Privia builds scaled provider networks with primary-care centric medical groups, risk-bearing entities, a physician-led governance structure, and the Privia Platform comprising an extensive suite of technology and service solutions. Privia collaborates with medical groups, health plans and health systems to optimize 1,300+ physician practices, improve the patient experience for 6.1+ million patients, and reward 5,600+ physicians and advanced practitioners for delivering high-value care.

Privia’s mission is to transform healthcare delivery to achieve better outcomes, lower costs, and improve the health of communities and the well-being of providers. For more information, visit priviahealth.com.

Safe Harbor Statement

This release may contain forward-looking statements within the meaning of the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements relate to our current expectations, projections and assumptions about our business, the economy and future events or conditions. They do not relate strictly to historical or current facts. Forward-looking statements can be identified by words such as “aims,” “anticipates,” “assumes,” “believes,” “estimates,” “expects,” “forecasts,” “future,” “intends,” “likely,” “may,” “outlook,” “plans,” “potential,” “projects,” “seeks,” “strategy,” “targets,” “trends,” “will,” “would,” “could,” “should,” and variations of such terms and similar expressions and references to guidance, although some forward-looking statements may be expressed differently. In particular, these include statements relating to, among other things: our future actions, business plans, objectives and prospects; and our future operating or financial performance and projections, including our full-year guidance for 2026. Factors or events that could cause actual results to differ may emerge from time to time and are difficult to predict. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results may differ materially from past results and those anticipated, estimated or projected. We caution you not to place undue reliance upon any of these forward-looking statements.

Factors related to these risks and uncertainties include, but are not limited to: the heavily regulated industry in which we operate, and any failure by us or our medical groups to comply with the extensive applicable healthcare laws and government regulations; the complexity of the legal framework governing our relationships with Medical Groups, some of which we do not own, and Privia providers, and the impact of legal challenges or shifting interpretations of applicable laws; the execution of our growth strategy, which may not prove viable and we may not realize expected results; difficulties timely implementing our proprietary end-to-end, cloud-based technology solution for Privia physicians and new medical groups; the high level of competition in our industry; challenges in successfully establishing a presence in new geographic markets; the impact of failures by or service disruptions at key third-party vendors, such as our primary electronic medical record vendor, athenahealth, Inc.; potential decreases in reimbursement rates by governmental and third-party payers, changes to payment terms or challenges negotiating and retaining favorable contracts with private third-party payers, and changes impacting our patient population; the financial and operational impact of our compliance with various complex and changing federal and state privacy and security laws and regulations related to our use, disclosure, and other processing of personal information and protected health information, including the Health Insurance Portability and Accountability Act of 1996; the impact of actual and potential security threats, cybersecurity incidents or privacy or other forms of data breaches involving us, our vendors or other third parties; the continued availability of qualified workforce, including staff at our medical groups, and the continued upward pressure on compensation for such workforce; and other risk factors described in our Annual Report on Form 10-K for the year ended December 31, 2025 and the Company’s subsequent Quarterly Reports on Form 10-Q. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.

Contact
Robert Borchert
SVP, Investor & Corporate Communications
IR@priviahealth.com
817.783.4841

BEDFORD, Mass., Nov. 02, 2026 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, announced data to be featured at the 2026 Clinical Trials on Alzheimer’s Disease (CTAD) Annual Meeting, taking place November 16 – November 19, 2026 in Boston, MA.

Presentation details are as follows:

Date & Time: Monday, November 16 (2:00 p.m. ET) – Tuesday, November 17 (5:30 p.m. ET)
Session Type: Poster
Session Title: MRI & Imaging

Poster Number: P077
Title: Detection of tau pathology in patients with early Alzheimer’s disease: Diagnostic performance of florquinitau F 18 PET in pivotal phase 3 studies
Presenter: Christopher Rowe, MD BMBS, FRACP, FAANMS, Director of Molecular Imaging Research at Austin Health

Poster Number: P082
Title: Minimal age dependence of astrocytic MAO-B with 18F-FDED PET Imaging in the Alzheimer’s disease spectrum
Presenter: Gerard Nisal Bischof, PD, Director Medical Imaging at Lantheus

About Lantheus 
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in New Jersey, Canada, Germany, Sweden, Switzerland and the United Kingdom, Lantheus has been providing radiopharmaceutical solutions for 70 years. For more information, visit www.lantheus.com.

Contacts:

Lantheus
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com

Melissa Downs
Executive Director, External Communications
646-975-2533
media@lantheus.com

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — Galloway Capital Partners, LLC announced that Galloway Capital, LP and its affiliates, Schedule 13D filers in PodcastOne, Inc. (NASDAQ: PODC), strongly support the Company’s decision to form a Special Committee of the Board of Directors to retain a financial advisor to evaluate strategic alternatives to maximize shareholder value.

Galloway believes PodcastOne’s public market valuation substantially understates the value of its content portfolio, advertising relationships and distribution capabilities, particularly to a strategic acquirer. The Company was recently ranked 6th among participating U.S. podcast publishers and networks measured by Podtrac, reaching approximately 5.8 million unique U.S. listeners.

“PodcastOne has expanded its revenue, programming and audience, yet we believe those achievements remain inadequately reflected in its share price,” said Bruce Galloway, Chief Executive Officer of Galloway Capital Partners. Based on our estimated annual revenue of $68 million to $75 million, applying an illustrative valuation range of 3 to 4x revenue implies an enterprise value of approximately $195 million to $300 million, or approximately $7.00 to $10 per share.   Recent transactions in the sector have been valued at 3 to 13x revenue.

About Galloway Capital Partners, LLC

Galloway Capital Partners, LLC is an investment firm focused on identifying undervalued public companies and engaging constructively to enhance shareholder value.

Contact:
Bruce Galloway
Chief Executive Officer
Galloway Capital Partners, LLC
bgalloway@gallowaycap.com

Forward-Looking Statements

This press release contains forward-looking statements that involve risks and uncertainties, including statements regarding potential value creation and strategic opportunities. Actual results may differ materially from those expressed or implied. Galloway undertakes no obligation to update these statements except as required by law.

Information regarding Galloway Capital Partners and certain matters referenced herein is contained in a Schedule 13D filed with the U.S. Securities and Exchange Commission on October 27, 2026, which is available at www.sec.gov.

Important Disclosures

Revenue estimates and valuation ranges reflect Galloway’s opinions and assumptions, are not Company guidance or an acquisition offer, and do not establish an available transaction price. Forward-looking statements involve risks and uncertainties; actual results may differ materially. No strategic review or transaction is assured. Galloway undertakes no obligation to update these statements except as required by law.

Vancouver, BC, Nov. 02, 2026 (GLOBE NEWSWIRE) — Humanoid Global Holdings Corp. (“Humanoid Global” or the “Company”) (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF), a publicly traded investment issuer focused on building and accelerating a portfolio of pioneering companies in the humanoid robotics and embodied AI sector, reports that its portfolio company Formic Technologies, Inc. (“Formic”), in which Humanoid Global holds a minority equity interest, has announced that it has raised US$50 million in growth capital (the “Financing”). According to Formic, the Financing comprises a Series B equity round led by Mercato Partners (“Mercato”), with participation from Light Ray Ventures, Lightscape Partners, Citi and other new and existing investors, together with debt financing from S2G Investments.

Formic, which describes itself as the commercialization platform for physical AI, delivers robotic automation to U.S. manufacturers through a Robots-as-a-Service model that bundles equipment, deployment software, field operations, maintenance, financing and performance monitoring into a single recurring monthly payment, with no upfront capital required from the customer. According to Formic, proceeds from the Financing will be used to accelerate its expansion from task-specific automation into general-purpose robotics, strengthen its AI and robotics capabilities, and expand into new applications such as metal fabrication, while deepening its presence in aerospace, space, defense, medical, energy and the broader U.S. industrial base.

According to Formic, it has operated robots in live production for more than five years and now runs hundreds of robots across more than 100 facilities in over 30 states, having accumulated more than 750,000 hours of live production. Formic reports fleet uptime of 99.6% and a customer renewal rate of 97%, with applications spanning palletizing, case packing, machine tending, kitting and assist work across food and beverage, consumer packaged goods, chemicals, aerospace, defense and packaging. Formic also reports that it now deploys robots into production approximately three times faster than it did a year ago, as data from each deployment informs subsequent installations.

Formic has stated that, as part of its move into general-purpose robotics, it is working with Physical Intelligence to adapt Physical Intelligence’s robotic foundation models for manufacturing applications using Formic’s production data and operational expertise. Formic assembles and tests its robots at its facility in Bolingbrook, Illinois, and develops new capabilities at its R&D center in Oakland, California. In connection with the Financing, Ryan Sanders, Managing Director at Mercato, has joined Formic’s Board of Directors.

Formic’s full announcement is available at businesswire.com.

Commenting on the Financing, Saman Farid, founder and CEO of Formic, noted that the gap between building a capable robot and making it productive on a real factory floor remains the industry’s central challenge, and that Formic is now extending its platform “from task-specific automation to general-purpose robotics.” He added that the model allows manufacturers to grow domestic output without committing significant capital to automation.

“Formic’s Series B is an encouraging validation of our investment thesis and of the value we believe exists in the deployment layer of physical AI,” said Sunny Ray, CEO of Humanoid Global. “A syndicate that includes Mercato Partners and Citi is backing a business with a meaningful operating record: hundreds of robots in live production, 99.6% uptime and a 97% renewal rate. As Formic extends its platform into general-purpose and humanoid robotics, we believe it has the potential to become an important channel through which embodied AI reaches American factory floors, and we are pleased that this progress is reflected in the value of our position.”

Humanoid Global previously announced a strategic investment in Formic as part of its mandate to support platforms that accelerate the adoption of autonomous robotics in manufacturing. The Company continues to view Formic as a core holding within its portfolio and consistent with its long-term thesis that commercialization and deployment infrastructure will be important to supporting widescale adoption of humanoid robotics, service robotics and orchestration technologies across key industrial markets.

About Humanoid Global Holdings Corp.

Humanoid Global Holdings Corp.  (CSE:ROBO, FWB:0XM1, OTCQB:RBOHF) (“Humanoid Global” or the “Company”) is a publicly traded investment issuer building a portfolio of pioneering companies in the growing humanoid robotics and embodied AI sector, investing in and accelerating their growth. It serves as a global investment platform providing liquidity and access to an actively managed portfolio spanning the value chain of this emerging ecosystem, including advanced software, hardware, and enabling technologies. Led by a team with a proven track record of scaling transformative technologies globally, the Company takes a long-term, partnership-oriented approach. It provides capital and strategic consultation on go-to-market strategies, regulatory pathways, and transaction advisory, while facilitating introductions to customers, suppliers, and strategic partners.

Learn more:
https://www.humanoidglobal.ai/

For further information, please contact:

Sunny Ray
Chief Executive Officer

finance@humanoidglobal.ai
info@humanoidglobal.ai
(604) 602-0001

CSE:ROBO
OTCQB:RBOHF
FWB:0XM1

ON BEHALF OF MANAGEMENT

Sunny Ray
Chief Executive Officer

Cautionary Note Regarding Forward-Looking Information

This news release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information in this news release includes, but is not limited to, statements regarding: Formic’s intended use of proceeds from the Financing; Formic’s expansion into general-purpose robotics and new applications and industries; Formic’s work with Physical Intelligence; and the Company’s expectations regarding its investment in Formic. Forward-looking information is based on certain assumptions made by the Company at the time such information was provided, including that: Formic will deploy the proceeds of the Financing as described; Formic will continue to operate and pursue its business objectives; and market conditions and demand for robotics and automation technology will remain favorable. The Company holds a minority equity interest in Formic and accordingly has a financial interest in Formic’s success; readers should consider this interest when evaluating the forward-looking information contained herein. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking information, including but not limited to: the risk that Formic may not achieve its stated business objectives or successfully expand into general-purpose robotics; the illiquid nature of the Company’s investment in a private company and the absence of a public market for Formic’s securities; the early-stage nature of general-purpose and humanoid robotics; the Company’s reliance on the performance of its portfolio companies, including Formic, in which the Company holds a minority equity interest; competition in the robotics and AI sectors; changes in applicable laws or regulations; general business, economic, and market conditions; and other risks described in the Company’s public filings available on SEDAR+ at www.sedarplus.ca. All forward-looking information in this news release is qualified in its entirety by this cautionary statement and speaks only as of the date hereof. The Company does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. Readers are cautioned not to place undue reliance on forward-looking information.

Certain information in this news release regarding Formic, the Financing, Formic’s operating metrics and its business plans has been derived from publicly available sources, including Formic’s news release dated October 22, 2026 and publicly available news coverage. The Company has not independently verified such information.

Amended offer includes 100% of outstanding pre-funded warrants and adds stapled warrants at $0.17 per warrant

Pre-funded warrant holders who tendered before the amendment must tender again

Offer extended to November 12, 2026

NEW YORK, Nov. 02, 2026 (GLOBE NEWSWIRE) — SkyAI, Inc. (Nasdaq: SKYA) (“SkyAI” or the “Company”) today announced amendments to its previously announced cash tender offer (the “Offer”), expanding the Offer to include 100% of the Company’s outstanding cash pre-funded warrants and cryptocurrency pre-funded warrants, as well as all outstanding cash stapled warrants and cryptocurrency stapled warrants. The Company has also extended the expiration of the Offer to one minute after 11:59 p.m., New York City time, on November 12, 2026, unless further extended or earlier terminated.

As previously announced, on October 27, 2026, Bastion Trading Limited and certain of its affiliates (together, “Bastion Trading”) entered into a tender support and settlement agreement (the “Agreement”) with the Company. Under the Agreement, Bastion Trading has agreed to tender all of its shares of common stock, pre-funded warrants and stapled warrants.

“By expanding the tender offer, we are providing all holders of our pre-funded warrants and stapled warrants with an equal opportunity for liquidity on the same terms,” said Paul Danner, Executive Chairman of SkyAI. “These amendments serve the interests of our security holders and allow management to remain focused on building our agentic AI financial platform.”

The Offer will expire at one minute after 11:59 p.m., New York City time, on November 12, 2026, unless further extended or earlier terminated. The Company reminds shareholders and warrant holders who wish to tender that brokers and other nominees may set earlier deadlines.

Holders who have not tendered their shares yet should take action by contacting their broker or the Information agent. Holders who tendered their shares before the amendment do not need to take further action. Holders of pre-funded warrants who tendered before the amendment must tender again using the new documents.

Holders who have not received a DocuSign, or who have questions about how to tender, should contact MacKenzie at (800) 322-2885 or (212) 929-5500, or by email at tenderoffer@mackenziepartners.com. The amended Offer to Purchase and the Letters of Transmittal are available at https://www.skyai.co/investors/tender-offer-materials. The Company’s answers to frequently asked questions are available at https://www.skyai.co/investors/tender-offer-faqs. The amended Offer to Purchase is available at https://www.sec.gov/Archives/edgar/data/1737995/000149315226049311/formsctoia.htm.

Terms of the Amended Offer

The Company is offering to purchase, in cash:

• up to 48,311,489 shares of common stock, or 95% of the class, at $3.00 per share;
• up to 5,137,615 cash pre-funded warrants and up to 10,463,001 cryptocurrency pre-funded warrants, or 100% of each class, at $3.00 per warrant less the $0.0001 exercise price;
• up to 41,054,034 cash stapled warrants and up to 22,159,638 cryptocurrency stapled warrants, or 100% of each class, at $0.17 per stapled warrant. The stapled warrants have an exercise price of $9.75 per share and;
• up to 3,955,293 strategic warrants, or 95% of the class, at $3.00 per warrant less the $0.0001 exercise price.

If all securities sought are tendered, the Company will pay approximately $214.3 million. The Company will pay for the securities purchased, and the related fees and expenses, from cash on hand of approximately $223 million. In the weeks leading up to the commencement of the Offer, the Company sold approximately 2 million SOL at an average price net of fees of $107.20 per SOL. The Company no longer holds any SOL and after the Offer is closed the Company will not be repurchasing SOL. The Offer is not subject to a financing condition.

The Company will announce the preliminary results of the Offer, including any expected proration, on the next business day after the Offer expires. The Company will pay for securities accepted in the Offer promptly after the Offer expires.

Subject to applicable law, the Company does not intend to withhold U.S. federal income tax from payments made to Non-U.S. Holders in the Offer. Holders are urged to consult their own tax advisors about the tax consequences of the Offer. See Section 14 of the Offer to Purchase.

How to Tender

Shares held through a broker. Holders whose shares are held by a broker, dealer, commercial bank, trust company or other nominee should contact that nominee and instruct it to tender. The nominee may set a deadline earlier than the expiration of the Offer, so holders should contact their nominee as soon as possible.

Shares registered with VStock. Holders whose shares are registered in their own name with VStock Transfer, LLC (“VStock”), the Company’s transfer agent, can tender by signing the first DocuSign sent by MacKenzie Partners, Inc. (“MacKenzie”), the Company’s Depositary and Information Agent, titled “SkyAI, Inc. – Tender Offer for Up to 95% of Outstanding Common Stock and Pre-Funded Warrants at $3.00 Each”. They can instead complete the physical Letter of Transmittal mailed to their registered address and send it to MacKenzie at 7 Penn Plaza, Suite 503, New York, NY 10001.

Pre-funded warrants. All pre-funded warrants are held with VStock. Holders can tender them by signing the second DocuSign which will be sent by MacKenzie later today, or by completing the new physical Letter of Transmittal mailed to their registered address. Tenders of pre-funded warrants made before the amendment, through the first DocuSign or the original Letter of Transmittal, are no longer valid. Holders who tendered pre-funded warrants before the amendment must tender them again with the second DocuSign or the new Letter of Transmittal.

Stapled warrants. All stapled warrants are held with VStock and none are held through a broker. Holders can tender them with the same second DocuSign or the new physical Letter of Transmittal.

Holders who already tendered shares. A tender of common stock made before the amendment, through a broker, the first DocuSign or the original Letter of Transmittal, stays in place under the amended Offer. These holders do not need to sign again or give their broker new instructions.

Warrant holders do not need to exercise their warrants before they tender. Holders of pre-funded warrants and strategic warrants will receive $2.9999 per warrant, the amount they would receive by exercising and tendering the underlying share. Holders may withdraw tendered securities at any time before the Offer expires.

No Recommendation Regarding Participation in the Offer

The Board of Directors of the Company (the “Board”) has approved the Offer and the amendments. However, neither SkyAI, the Board, the Company’s directors or officers, nor the depositary and information agent makes any recommendation to any shareholder or warrant holder as to whether the shareholder or warrant holder should tender or refrain from tendering shares or warrants in the Offer or as to the number of shares or warrants a shareholder or warrant holder should tender.

Each shareholder and warrant holder must make his, her or its own decision regarding whether to participate in the Offer and, if so, how many shares or warrants to tender. Shareholders and warrant holders are urged to carefully review the Offer Materials (as defined below) and to consult their own financial, tax and legal advisors in making that decision.

Additional Information Regarding the Offer

This communication is not an offer to buy nor a solicitation of an offer to sell any securities of the Company. The solicitation and offer to buy shares, cash pre-funded warrants, cryptocurrency pre-funded warrants, strategic warrants, cash stapled warrants and cryptocurrency stapled warrants are being made solely pursuant to the Offer to Purchase, the related Letters of Transmittal and the other tender offer materials, as amended (the “Offer Materials”), that the Company has filed as part of a tender offer statement on Schedule TO with the SEC, as amended. Investors may obtain a free copy of these materials and all other documents filed by the Company with the SEC at the website maintained by the SEC at www.sec.gov. Investors may also obtain, at no charge, any such documents filed with or furnished to the SEC by the Company under the “Investors” section of the Company’s website at www.skyai.co. INVESTORS AND SECURITY HOLDERS ARE ADVISED TO READ THESE DOCUMENTS, INCLUDING THE OFFER MATERIALS OF THE COMPANY AND ANY AMENDMENTS OR SUPPLEMENTS THERETO, AS WELL AS ANY OTHER DOCUMENTS RELATING TO THE OFFER THAT ARE FILED WITH THE SEC, CAREFULLY AND IN THEIR ENTIRETY PRIOR TO MAKING ANY DECISIONS WITH RESPECT TO WHETHER TO TENDER THEIR SHARES, CASH PRE-FUNDED WARRANTS, CRYPTOCURRENCY PRE-FUNDED WARRANTS, STRATEGIC WARRANTS, CASH STAPLED WARRANTS AND CRYPTOCURRENCY STAPLED WARRANTS INTO THE OFFER BECAUSE THEY CONTAIN IMPORTANT INFORMATION, INCLUDING THE TERMS AND CONDITIONS OF THE OFFER. THE OFFER MATERIALS CAN ALSO BE FOUND ON THE COMPANY’S WEBSITE AT https://www.skyai.co/investors/tender-offer-materials.

Questions and requests for assistance, or for additional copies of the Offer Materials, may be directed to MacKenzie Partners, Inc. at (800) 322-2885 or (212) 929-5500, or by email at tenderoffer@mackenziepartners.com.

About SkyAI

SkyAI, Inc. (Nasdaq: SKYA) is an artificial intelligence company building an agentic finance platform for the Global South. For additional information, please visit www.skyai.co.

Forward-Looking Statements

This press release contains “forward-looking statements”. All statements in this release other than statements of historical fact are forward-looking statements, including statements regarding the Offer, including its timing, terms, funding and completion, the Company’s strategy and product roadmap and the potential opportunities such initiatives may create. Forward-looking statements are based on current expectations, assumptions, and beliefs, and involve risks and uncertainties that could cause actual results to differ materially.

Risks and uncertainties that could cause results to differ from expectations include: (i) uncertainties as to the timing and terms of the Offer; (ii) the risk that the Offer may not be completed in a timely manner or at all; (iii) uncertainties as to the percentage of the Company’s shareholders and/or warrant holders tendering their shares or warrants in the Offer; (iv) the possibility that any or all of the various conditions to the consummation of the Offer, including the minimum condition for each class, may not be satisfied or waived; (v) the occurrence of any event, change or other circumstance that could give rise to the termination of the Offer; (vi) the effect of the announcement or pendency of the Offer on the Company’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, its operating results and business generally or the trading market for its common stock; (vii) risks related to the Offer diverting management’s attention from the Company’s ongoing business operations; (viii) the risk that shareholder litigation in connection with the Offer may result in significant costs of defense, indemnification and liability; (ix) the Company’s ability to achieve the benefits contemplated by the Offer; and (x) risks and uncertainties pertaining to the Company’s business and the risks and uncertainties detailed in the Company’s Annual Report on Form 10-K for the year ended December 31, 2025 and its other filings with the SEC, as well as the Offer Materials to be filed by the Company in connection with the Offer.

Forward-looking statements speak only as of the date of this press release. The Company undertakes no obligation to update or revise these statements, whether as a result of new information, future developments, or otherwise, except as required by law.

Media Contact
Edelman Smithfield
SkyAI@edelmansmithfield.com

Depositary and Information Agent
MacKenzie Partners, Inc.
(800) 322-2885 or (212) 929-5500
tenderoffer@mackenziepartners.com

New Fluke ii1050 and ii1030 acoustic imagers combine advanced detection, thermal imaging support, and on-device reporting to quickly uncover issues and reduce unplanned downtime

Everett, Washington, Nov. 02, 2026 (GLOBE NEWSWIRE) — The costliest threats to productivity and profitability are often the ones maintenance teams can’t see. Hidden compressed air leaks waste energy around the clock, while developing electrical and mechanical issues can escalate into safety incidents, equipment failures and unplanned downtime. As industrial organizations face rising energy costs, growing reliability expectations and ongoing workforce shortages, identifying these issues quickly has become more critical than ever.

Organizations need technologies that can uncover hidden issues faster, simplify inspections and enable more confident maintenance decisions. To meet that need, Fluke today introduced the Fluke ii1050 and ii1030 Acoustic Imagers, a new generation of imaging designed to deliver greater acoustic performance in a significantly smaller, lighter platform while simplifying the path from detection to action.

Approximately 40% smaller than previous-generation models and weighing just 1.2 kilograms, the ii1050 and ii1030 make long inspections more comfortable and confined or hard-to-reach areas easier to access. Despite the significantly smaller form factor, the imagers retain the same-size display, now with an anti-glare screen for improved visibility, while an IP54-rated design provides greater protection for demanding industrial environments.

Equipped with 202 microphones, up from 64 in previous-generation models, the cameras can detect fainter sounds and pinpoint their source with greater precision. A high-resolution 13-megapixel camera provides clear visual context, while on-device reporting and an integrated flashlight help teams inspect, diagnose, and document issues in the field. Support for the new TC03A plug-in thermal camera adds thermal imaging to the inspection workflow, giving technicians additional visual context when investigating equipment conditions.

“Maintenance is increasingly less about responding to failures reactively and more about preventing them,” said Tako Feron, Senior Product Manager, Acoustic Imaging, at Fluke. “More complex work means experienced technicians are increasingly scarce, so teams need technologies that turn complex data into clear, insights in the field. The Fluke ii1050 and ii1030 reveal issues that might otherwise go undetected and present information in a way that is intuitive and relevant to the user, enabling faster, more confident decisions on the job. This also supports sustainability by reducing energy waste, improving asset reliability and reducing costly disruptions.”

The ii1050 and ii1030 enable maintenance teams to quickly locate compressed air, gas and vacuum leaks, detect electrical partial discharge, and identify developing mechanical issues from a safe distance. By transforming sound into clear visual insights, the cameras accelerate troubleshooting, support more confident maintenance decisions and help organizations improve reliability while reducing energy waste.

The Fluke ii1050 and ii1030 give maintenance teams the tools to:

• Find compressed air and gas leaks earlier to reduce energy waste and operating costs.
• Detect partial discharge from a safe distance to identify electrical issues before they escalate.
• Identify developing mechanical issues before they lead to equipment failure and costly unplanned downtime
• Inspect more assets in less time with enhanced acoustic performance and a smaller, lighter design.
• Turn findings into action faster with on-device tools to assess, prioritize and report inspection results.

The ii1050 and ii1030 combine leak detection, partial-discharge inspection and mechanical anomaly detection in a single platform, enabling maintenance teams to move from inspection to action faster while supporting reliability, safety and energy-efficiency initiatives.

To learn more about the new Acoustic Imagers, please visit the ii1050 and ii1030 product pages at Fluke.com.

About Fluke
Founded in 1948, Fluke Corporation is the world leader in compact, professional electronic test tools and software for measurement and condition monitoring. Fluke customers include technicians, engineers, electricians, maintenance managers and metrologists who install, troubleshoot and maintain industrial, electrical and electronic equipment and calibration processes.

FLUKE is a registered trademark of Fluke Corporation. For more information, visit www.fluke.com.

Media Contacts:

Dave Smith
Fluke Corporation
dave.smith@fluke.com

Olivia Kline
Fluke Corporation
olivia.kline@fluke.com

Q: How do the ii1050 and ii1030 help organizations improve reliability and reduce energy waste?
A: The ii1050 and ii1030 help organizations identify issues that often go unnoticed until they become costly problems. By revealing hidden air and gas leaks, detecting partial discharge activity and identifying developing mechanical issues early, maintenance teams can prioritize corrective action, reduce energy losses, improve asset reliability and avoid unplanned downtime.

Q: How do the ii1050 and ii1030 help maintenance teams do more with fewer resources?
A: The ii1050 and ii1030 combine advanced acoustic imaging, thermal imaging support and on-device reporting in a smaller, lighter design that simplifies inspections and accelerates decision-making. By helping users find issues faster, inspect more assets in less time and document results directly in the field, the cameras improve technician productivity while reducing workflow complexity.

Q: How do the Fluke ii1050 and ii1030 differ from other Fluke acoustic imagers?
A: The ii1050 and ii1030 are Fluke’s most capable acoustic imagers to date, combining enhanced acoustic performance, expanded diagnostic capabilities and streamlined reporting in a significantly smaller, lighter design. Compared to previous-generation models, they feature a 202-microphone array, up from 64 microphones, improving the ability to detect and pinpoint smaller, fainter and more closely spaced sound sources. The cameras also introduce on-device reporting, thermal imaging support, an integrated flashlight, enhanced LeakQ™ and PDQ™ algorithms, expanded storage capacity and improved environmental protection, helping maintenance teams inspect more assets, make faster decisions and document findings more efficiently.

Attachments

• Fluke Unveils Its Most Powerful Acoustic Imagers in a Smaller, Lighter Design
• Fluke Unveils Its Most Powerful Acoustic Imagers in a Smaller, Lighter Design

CONTACT: Dave Smith
Fluke Corporation
dave.smith@fluke.com

LAWRENCEVILLE, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that the Company will host a conference call at 11:00 a.m. EST on Thursday, November 12, 2026 to discuss financial results for the quarter ended September 30, 2026 and provide an update on its clinical development program with IMNN-001, a DNA-based interleukin-12 (IL-12) immunotherapy, including progress in advancing Phase 3 clinical development of IMNN-001 in newly diagnosed advanced ovarian cancer.

To participate in the call, please dial (800) 715-9871 (U.S. and Canada/Toll Free) or (646) 307-1963 (U.S./Toll) and ask for the IMUNON Third Quarter 2026 Financial Results Call (Conference ID 4174261). A live webcast of the call will also be available here.

An audio replay of the call will be available for 90 days and can be accessed at (800) 770-2030 (U.S. and Canada/Toll Free) or (609) 800-9909 (U.S./Toll) using replay access code 4174261#.

About IMUNON

IMUNON is a clinical-stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the body’s natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. IMUNON is developing its non-viral DNA-based gene therapy technology across its modalities. The lead modality, TheraPlas^®, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors where an immunological approach is deemed promising.

The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy being developed for the localized treatment of advanced ovarian cancer. IMNN-001 has been evaluated in multiple clinical trials including one Phase 2 clinical trial (OVATION 2) and is currently being studied in an ongoing Phase 3 clinical trial (OVATION 3). IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site. Additionally, the Company has completed dosing in a first-in-human study of its COVID-19 booster vaccine (IMNN-101). The Company will continue to leverage these modalities and to advance, either directly or through partnership, the technological frontier of plasmid DNA to better serve patients with difficult-to-treat conditions. For more information, please visit www.imunon.com.

Forward-Looking Statements

IMUNON wishes to inform readers that forward-looking statements in this release are made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, including, but not limited to, statements regarding the timing and enrollment of the Company’s clinical trials, the potential of any therapies developed by the Company to fulfill unmet medical needs, the market potential for the Company’s products, if approved, the potential efficacy and safety profile of our product candidates, and the Company’s plans and expectations with respect to its development programs more generally, are forward-looking statements. We generally identify forward-looking statements by using words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances). Readers are cautioned that such forward-looking statements involve risks and uncertainties including, without limitation, uncertainties relating to unforeseen changes in the course of research and development activities and in clinical trials, including the fact that interim results are not necessarily indicative of final results; the uncertainties of and difficulties in analyzing interim clinical data; the significant expense, time and risk of failure in conducting clinical trials; the need for IMUNON to evaluate its future development plans; possible actions by customers, suppliers, competitors or regulatory authorities; and other risks detailed from time to time in IMUNON’s filings with the Securities and Exchange Commission. IMUNON assumes no obligation, except to the extent required by law, to update or supplement forward-looking statements that become untrue because of subsequent events, new information or otherwise.

Investor Contact:
Valter Pinto
KCSA Strategic Communications
212-896-1254
imunon@kcsa.com